PH set to sign vaccine deal with AstraZeneca | Inquirer News

PH set to sign vaccine deal with AstraZeneca

CHEAPEST SO FAR The COVID-19 vaccine of AstraZeneca will cost only $5 for two shots.—AFP

MANILA, Philippines — The Philippine government may sign a deal with the British Swedish multinational and biopharmaceutical company AstraZeneca by the end of this month for the supply of its COVID-19 vaccine once the UK government issues a health regulatory authorization, the country’s vaccine czar said on Monday.

In his report to President Rodrigo Duterte, Secretary Carlito Galvez Jr. said the government and AstraZeneca could sign a deal on Dec. 28 or 29 for 20 million and 10 million doses for the local governments and the private sector, respectively.


This is once Britain’s Medicine and Health Care Products Regulatory Agency grants authorization for the vaccine, Galvez said.

AstraZeneca pegged its price at only $5, or more or less P500 for two jabs of its COVID-19 vaccine.


The vaccine, known as AZD1222, was co-developed with the Oxford University’s Jenner Institute and Oxford Vaccine Group. Administered by intramuscular injection, the vaccine uses as a vector a modified chimpanzee adenovirus.

No cash advance

Galvez said the government was also negotiating with Serum Institute of India for the supply of another type of COVID-19 vaccine and a meeting with the institute’s country representative was scheduled for Wednesday.

The Serum Institute, which promised to deliver 30 million doses, will comply with Republic Act No. 9184 or the Government Procurement Reform Act and will not ask for a cash advance, giving the government more flexibility, according to Galvez. Under a partnership with America’s Novavax Inc., the vaccines will be manufactured in India.

Novavax’s candidate vaccine, NVZ-CoV2373, is being developed with support of the Coalition for Epidemic Preparedness Innovations and is currently undergoing Phase 3 trials.

“So all in all, if the signing pushes through, we will have 60 million [doses] for the second and third quarter,” Galvez said.

The House Makabayan bloc is seeking an investigation of the government’s COVID-19 vaccination program after an “apparent conflict” within the Duterte administration on the procurement of the vaccine.

“Even before the first government officially procured doses of vaccine arrived, controversies had already hounded the procurement process, with alleged issues of supposed conflict of interest, corruption and profiteering surfacing,” the Makabayan bloc said in filing the House resolution.


In their resolution, the Makabayan bloc wanted the Defeat COVID-19 Ad-Hoc Committee to launch a formal inquiry into the government’s mass vaccination program for COVID-19.

The group said that “due to the lack of prompt action of the government to track, test and isolate the first few cases, the virus spread like wildfire and increased a hundredfold in just a few weeks.” INQ

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: AstraZeneca, Coronavirus, COVID-19, Health, pandemic, vaccine, Virus
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

News that matters

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2023 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.